Equillium Stock Price, News & Analysis

Equillium plans to commence a global Phase 3 COVID-19 trial, named EQUINOX, in Q4 2020, following FDA approval. This study will assess the efficacy of itolizumab in hospitalized patients suffering from acute respiratory distress syndrome (ARDS). Enrolling 800 patients, the trial will evaluate recovery rates, mortality, and safety profiles, with initial data expected by mid-2021. The company aims to address critical healthcare needs amid the COVID-19 crisis and anticipates that successful outcomes could support a Biologic License Application (BLA).

Equillium, Inc. (Nasdaq: EQ) announced the presentation of data at the European Respiratory Society International Congress 2020, highlighting the potential of the CD6-ALCAM pathway as a therapeutic target in uncontrolled asthma. The findings show that soluble ALCAM levels were elevated in patients with severe asthma. The company’s ongoing clinical development of itolizumab aims to treat moderate-to-severe uncontrolled asthma, emphasizing its role in modulating immune responses. Current asthma treatments are inadequate for many patients, underlining the need for new therapies.

Equillium, Inc. (Nasdaq: EQ) announces the completion of a pre-IND meeting with the FDA regarding its drug itolizumab for COVID-19 treatment. The FDA provided positive feedback, enabling Equillium to finalize a protocol and plan to submit a U.S. IND application in October 2020. The company aims to start a global Phase 3 clinical trial in Q4 2020. Successful outcomes may support a Biologic License Application. This milestone is crucial for Equillium's plan to treat COVID-19 patients, utilizing itolizumab's unique immune-modulating properties.

Equillium, Inc. (Nasdaq: EQ) has announced that CEO Bruce Steel and CMO Krishna Polu will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11 AM ET. The virtual event will feature a live webcast accessible on Equillium's website, with replays available for 30 days. Equillium focuses on developing products for severe autoimmune disorders, with its lead candidate, itolizumab, targeting T cell activity. Itolizumab shows promise in treating cytokine release syndrome in COVID-19 patients and is being explored for other severe conditions.

Equillium, Inc. (Nasdaq: EQ) has completed its underwritten public offering of 5,000,000 shares of common stock, priced at $7.00 per share, raising gross proceeds of $35 million. Joint book-running managers for the offering included Jefferies, SVB Leerink, and Stifel. The offering aims to advance Equillium's clinical development of its monoclonal antibody, itolizumab, which targets severe autoimmune disorders. The SEC has approved the registration statement associated with this offering, and the final prospectus is available on their website.

Equillium, Inc. (Nasdaq: EQ) announced a public offering of 5 million shares at $7.00 per share, with potential proceeds of approximately $35 million. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Funds will support the development of product candidates, potential acquisitions, and general corporate purposes. The closing is anticipated on August 18, 2020. Jefferies, SVB Leerink, and Stifel serve as joint book-running managers.

Equillium, Inc. (Nasdaq: EQ) announced its intention to offer shares of its common stock in an underwritten public offering, aiming to sell shares exclusively from the company. Underwriters may purchase an additional 15% within 30 days. Proceeds will fund development of product candidates, potential acquisitions, and general corporate purposes. Jefferies, SVB Leerink, and Stifel are joint book-running managers. The offering is subject to market conditions, and details will be available in the prospectus supplement filed with the SEC.

Equillium, Inc. (Nasdaq: EQ) reported its Q2 2020 financial results, showcasing significant progress in its development of itolizumab for severe autoimmune disorders. Interim data from the EQUATE trial indicates a 71% complete response rate in acute graft-versus-host disease (aGVHD) patients. The company also highlighted positive results from Biocon's COVID-19 trial, leading to emergency use approval in India. Despite a net loss of $6.5 million, cash reserves stood at $42.6 million. Upcoming catalysts include new trials for itolizumab in COVID-19 and other conditions.

Equillium (Nasdaq: EQ) announced positive interim results from the EQUATE study involving itolizumab for treating acute graft-versus-host disease (aGVHD). In the first two cohorts, five of seven patients achieved complete responses, with a 71% overall response rate. Itolizumab has been well tolerated, prompting plans for dose escalation. Additionally, a Pre-IND meeting request has been submitted to the FDA to explore itolizumab’s use in COVID-19 patients, building on supportive data from Biocon’s studies. This underscores Equillium’s commitment to developing innovative therapies for severe autoimmune conditions.